GlassScriptPhysician profile
Bruce J Gould
NPI 1326042706
$23,214.39
in general payments reported to CMS, 2019-2025
47 companies · $970 in 2025
The $970 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $350 · 2021: $377 · 2022: $3,626 · 2023: $978 · 2024: $1,728 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,472 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.38 |
| Education | $203.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,902.24 | 2019-2025 | |
| Genentech USA, INC. | $6,503.60 | 2019-2025 | Venclexta, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $3,124.42 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Secura Bio, INC. | $1,255.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $500.68 | 2019-2025 | |
| Janssen Biotech, INC. | $325.59 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $312.59 | 2020-2025 | Enhertu, Injectafer |
| Seagen INC. | $275.36 | 2019-2023 | Padcev |
| Merck Sharp & Dohme LLC | $257.94 | 2019-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $248.34 | 2019-2025 | Opdivo |
| Abbvie INC. | $233.44 | 2019-2025 | |
| Celgene Corporation | $231.24 | 2021-2025 | Reblozyl |
| Genzyme Corporation | $227.44 | 2024-2025 | |
| Intera Oncology, INC | $222.50 | 2024 | Intera |
| Pharmacyclics LLC, An Abbvie Company | $195.26 | 2019-2023 | Imbruvica |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.